ev鎵戝厠琛€娑茬槫绠＄嚎20澶氶」鐮旂┒鎴愭灉鍏ラ€夌67灞婄編鍥借娑插浼氾紙ASH锛夊勾浼
2025骞11鏈6鏃锛屼腑鍥藉寳浜€斺€鐢熺墿鍖昏嵂楂樼鎶€鍏徃ev鎵戝厠锛堜笂浜ゆ墍浠ｇ爜锛688428锛涢娓仈浜ゆ墍浠ｇ爜锛09969锛変粖澶╁甯锛屽叕鍙歌嚜涓荤爺鍙戠殑鏂板瀷BCL2鎶戝埗鍓Mesutoclax鍜屾柊鍨BTK鎶戝埗鍓傚ゥ甯冩浛灏肩殑20澶氶」鐮旂┒鎴愭灉鍏ラ€夌67灞婄編鍥借娑插鍗忎細锛ASH锛夊勾浼锛屽寘鎷2椤瑰彛澶存姤鍛婂拰20涓捣鎶ュ睍绀銆
鍏朵腑锛Mesutoclax鍏辨湁涓夐」鐮旂┒鍏ラ€夋娆SH骞翠細锛歁esutoclax娌荤枟濂楃粏鑳炴穻宸寸槫锛圡CL锛夌殑鐮旂┒鍏ラ€夊彛澶存姤鍛锛孧esutoclax娌荤枟鎱㈡€ф穻宸寸粏鑳炵櫧琛€鐥/灏忔穻宸寸粏鑳炴穻宸寸槫锛圕LL/SLL锛夊拰鎬ユ€ч珦绯荤櫧琛€銆偹婱L锛夌殑鐮旂┒鍏ラ€夋捣鎶ュ睍绀銆鍏蜂綋濡備笅锛
鍙ｅご鎶ュ憡
鏍囬锛Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients
Mesutoclax鍗曡嵂娌荤枟澶嶅彂/闅炬不鎬у缁嗚優娣嬪反鐦ゆ偅鑰呯殑鐤楁晥鍜岃€愬彈鎬锛氬湪鏃㈠線瀵BTK鎶戝埗鍓傝€愯嵂鐨勬偅鑰呬腑鏄剧ず鍑洪珮缂撹В鐜
鎶ュ憡缂栧彿锛887
鎶ュ憡鐜妭锛623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Single Agent and Combination therapy for MCL
623. 濂楃粏鑳炴穻宸寸槫銆佹护娉℃穻宸寸槫銆佸崕姘忓法鐞冭泲鐧借鐥囧強鍏朵粬鎯版€B缁嗚優娣嬪反鐦わ細涓村簥涓庢祦琛岀梾瀛锛氬崟鑽不鐤椾笌鑱斿悎娌荤枟濂楃粏鑳炴穻宸寸槫
缇庡浗涓滈儴鏃堕棿锛2025骞12鏈8鏃ワ紙鏄熸湡涓€锛03:45 PM - 04:00 PM
鍦扮偣锛OCCC - Tangerine Ballroom F1
涓昏浣滆€咃細鍛ㄥ彲鏍
娴锋姤灞曠ず1
鏍囬锛Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Mesutoclax锛ICP-248锛夊崟鑽不鐤楁垨鑱斿悎濂ュ竷鏇垮凹娌荤枟鎱㈡€ф穻宸寸粏鑳炵櫧琛€鐥/灏忔穻宸寸粏鑳炴穻宸寸槫锛CLL/SLL锛夋樉绀哄嚭浠や汉榧撹垶鐨勭枟鏁堝拰瀹夊叏鎬
鎶ュ憡缂栧彿锛5677
鎶ュ憡鐜妭锛642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III
642. 鎱㈡€ф穻宸寸粏鑳炵櫧琛€銆傛淇呯伩鑲撻鑳佲姍锛氭捣鎶 III
缇庡浗涓滈儴鏃堕棿锛2025骞12鏈8鏃ワ紙鏄熸湡涓€锛06:00 PM - 08:00 PM
鍦扮偣锛OCCC - West Halls B3-B4
涓昏浣滆€锛氭娲
娴锋姤灞曠ず2
鏍囬锛Safety, tolerability and efficacy of mesutoclax to treat patients with myeloid malignancies
Mesutoclax娌荤枟楂撶郴鎭舵€ц偪鐦ょ殑瀹夊叏鎬銆佽€愬彈鎬у拰鏈夋晥鎬
鎶ュ憡缂栧彿锛3417
鎶ュ憡鐜妭锛616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II
616. 鎬ユ€ч珦绯荤櫧琛€銆傝矇鑺晝鐮糕敧閿涜穻璧寸槦锛氭捣鎶 II
缇庡浗涓滈儴鏃堕棿锛2025骞12鏈7鏃ワ紙鏄熸湡鏃ワ級06:00 PM - 08:00 PM
鍦扮偣锛OCCC - West Halls B3-B4
涓昏浣滆€咃細姹熷€
濂ュ竷鏇垮凹20澶氶」鐮旂┒鍏ラ€夋娆SH骞翠細锛屽寘鎷1椤瑰彛澶存姤鍛婏紝20澶氫釜娴锋姤灞曠ず鍜屽湪绾垮彂甯锛屾秹鍙婄柧鐥呴鍩熷寘鎷竟缂樺尯娣嬪反鐦わ紙MZL锛銆佸師鍙戜腑鏋㈢缁忕郴缁熸穻宸寸槫锛圥CNSL锛銆佹參鎬ф穻宸寸粏鑳炵櫧琛€鐥/灏忔穻宸寸粏鑳炴穻宸寸槫锛圕LL/SLL锛夊拰寮ユ极鎬уぇB缁嗚優娣嬪反鐦わ紙DLBCL锛銆備富瑕佺爺绌跺涓锛
鍙ｅご鎶ュ憡
鏍囬锛Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL: A prospective biomarker study
娌荤枟涓湡鑴戣剨娑ctDNA鍜MYD88娓呴櫎鍦ㄩ娴嬫柊璇婃柇鍘熷彂涓灑绁炵粡绯荤粺娣嬪反鐦ゆ偅鑰呭鍩轰簬濂ュ竷鏇垮凹鐨勮瀵肩枟娉曠殑缂撹В鍜岀敓瀛樻柟闈紭浜PET-CT锛氫竴椤瑰墠鐬绘€х敓鐗╂爣蹇楃墿鐮旂┒
鎶ュ憡缂栧彿锛59
鎶ュ憡鐜妭锛627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Front-line BTKi-based Combination Therapy in DLBCL and PCNSL
627. 渚佃鎬ф穻宸寸槫锛氶澏鍚戝拰鑽墿娌荤枟鈥斺€斿熀浜BTK鎶戝埗鍓傜殑鑱斿悎鐤楁硶娌荤枟寮ユ极澶B缁嗚優娣嬪反鐦わ紙DLBCL锛夊拰鍘熷彂涓灑绁炵粡绯荤粺娣嬪反鐦わ紙PCNSL锛
缇庡浗涓滈儴鏃堕棿锛2025骞12鏈6鏃ワ紙鏄熸湡鍏級10:30 AM - 10:45 AM
鍦扮偣锛OCCC - Tangerine Ballroom F3-4
涓昏浣滆€咃細鐩涚珛闇
娴锋姤灞曠ず1
鏍囬锛Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)
濂ュ竷鏇垮凹鑱斿悎濂ュΕ鐝犲崟鎶楁不鐤楄竟缂樺尯娣嬪反鐦ょ殑鍒濇鍒嗘瀽锛Orion鐮旂┒锛
鎶ュ憡缂栧彿锛5379
鎶ュ憡鐜妭锛623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III
623. 濂楃粏鑳炴穻宸寸槫銆佹护娉℃穻宸寸槫銆佸崕姘忓法鐞冭泲鐧借鐥囧強鍏朵粬鎯版€B缁嗚優娣嬪反鐦锛氫复搴婁笌娴佽鐥呭锛氭捣鎶III
缇庡浗涓滈儴鏃堕棿锛2025骞12鏈8鏃ワ紙鏄熸湡涓€锛06:00 PM - 08:00 PM
鍦扮偣锛OCCC - West Halls B3-B4
涓昏浣滆€锛氭槗鏍戝崕
娴锋姤灞曠ず2
鏍囬锛Preliminary study results of orelabrutinib in combination with rituximab for treatment-Na?ve marginal zone lymphoma: A prospective single-arm clinical trial
濂ュ竷鏇垮凹鑱斿悎鍒╁Ε鏄斿崟鎶楁不鐤楀垵娌昏竟缂樺尯娣嬪反鐦ょ殑鍒濇鐮旂┒缁撴灉锛氫竴椤瑰墠鐬绘€у崟鑷備复搴婅瘯楠
鎶ュ憡缂栧彿锛3580
鎶ュ憡鐜妭锛623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
623. 濂楃粏鑳炴穻宸寸槫銆佹护娉℃穻宸寸槫銆佸崕姘忓法鐞冭泲鐧借鐥囧強鍏朵粬鎯版€B缁嗚優娣嬪反鐦锛氫复搴婁笌娴佽鐥呭锛氭捣鎶II
缇庡浗涓滈儴鏃堕棿锛2025骞12鏈7鏃ワ紙鏄熸湡鏃ワ級06:00 PM - 08:00 PM
鍦扮偣锛OCCC - West Halls B3-B4
涓昏浣滆€锛氬緪鍏
娴锋姤灞曠ず3
鏍囬锛Orelabrutinib plus bendamustine-rituximab (OBR) Versus Bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk Mantle Cell Lymphoma (MCL)
濂ュ竷鏇垮凹鑱斿悎鑻揪鑾徃姹€-鍒╁Ε鏄斿崟鎶楋紙OBR锛夊姣旇嫰杈捐帿鍙告眬-鍒╁Ε鏄斿崟鎶楋紙BR锛夋不鐤椾笉閫傚悎绉绘鐨勪腑楂樺嵄濂楃粏鑳炴穻宸寸槫锛MCL锛
鎶ュ憡缂栧彿锛3599
鎶ュ憡鐜妭锛623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
623. 濂楃粏鑳炴穻宸寸槫銆佹护娉℃穻宸寸槫銆佸崕姘忓法鐞冭泲鐧借鐥囧強鍏朵粬鎯版€B缁嗚優娣嬪反鐦锛氫复搴婁笌娴佽鐥呭锛氭捣鎶II
缇庡浗涓滈儴鏃堕棿锛2025骞12鏈7鏃ワ紙鏄熸湡鏃ワ級06:00 PM - 08:00 PM
鍦扮偣锛OCCC - West Halls B3-B4
涓昏浣滆€锛氱帇榛
娴锋姤灞曠ず4
鏍囬锛Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China
涓浗澶ц妯＄湡瀹炰笘鐣岀爺绌剁殑鍒濇缁撴灉锛氫笉鍚岄仐浼犱簹鍨DLBCL鐨勬不鐤楁ā寮忓拰缁撴灉
鎶ュ憡缂栧彿锛3689
鎶ュ憡鐜妭锛627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster II
627. 渚佃鎬ф穻宸寸槫锛氶澏鍚戝拰鑽墿娌荤枟锛氭捣鎶II
缇庡浗涓滈儴鏃堕棿锛2025骞12鏈7鏃ワ紙鏄熸湡鏃ワ級06:00 PM - 08:00 PM
鍦扮偣锛OCCC - West Halls B3-B4
涓昏浣滆€咃細璧电淮鑾/璁稿江楣
娴锋姤灞曠ず5
鏍囬锛Pomalidomide, rituximab, and orelabrutinib in combination with polatuzumab vedotin for newly diagnosed diffuse large B-cell lymphoma in elderly, unfit, or frail patients: a prospective phase II study
娉婇┈搴﹁兒銆佸埄濡ユ様鍗曟姉鍜屽ゥ甯冩浛灏艰仈鍚堢淮娉婂Ε鐝犲崟鎶楁不鐤楄€佸勾銆佷綋寮辨垨涓嶉€傚悎寮哄寲鐤楃殑鏂拌瘖鏂讥婕€уぇB缁嗚優娣嬪反鐦ゆ偅鑰咃細涓€椤瑰墠鐬绘€р叀鏈熶复搴婄爺绌
鎶ュ憡缂栧彿锛1912
鎶ュ憡鐜妭锛627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster I
627. 渚佃鎬ф穻宸寸槫锛氶澏鍚戝拰鑽墿娌荤枟锛氭捣鎶I
缇庡浗涓滈儴鏃堕棿锛2025骞12鏈6鏃ワ紙鏄熸湡鍏級05:30 PM - 07:30 PM
鍦扮偣锛OCCC - West Halls B3-B4
涓昏浣滆€咃細鏇叉槍鑿
鏈ASH骞翠細灏嗕簬2025骞12鏈6-9鏃ュ湪缇庡浗浣涚綏閲岃揪宸炲ゥ鍏板涓惧姙銆
鍏充簬ev鎵戝厠
ev鎵戝厠锛堜笂浜ゆ墍浠ｇ爜锛688428锛涢娓仈浜ゆ墍浠ｇ爜锛09969锛夋槸涓€瀹跺晢涓氬寲闃舵鐨勭敓鐗╁尰鑽珮绉戞妧鍏徃锛屼笓娉ㄤ簬鎭舵€ц偪鐦ゅ強鑷韩鍏嶇柅鎬х柧鐥呴鍩熺殑涓€绫绘柊鑽爺鍒銆傚叕鍙哥幇鏈夊涓柊鑽骇鍝佸浜庡晢涓氬寲銆佷复搴婂強涓村簥鍓嶇爺鍙戦樁娈銆傚叕鍙稿湪鍖椾含銆佸崡浜銆佷笂娴枫€佸箍宸銆侀娓互鍙婄編鍥借鏈夊垎鏀満鏋銆
